Brokers Set Expectations for SLDB Q1 Earnings

Solid Biosciences Inc. (NASDAQ:SLDB) – Stock analysts at Leerink Partnrs issued their Q1 2026 earnings per share estimates for Solid Biosciences in a note issued to investors on Wednesday, August 13th. Leerink Partnrs analyst J. Schwartz expects that the company will earn ($0.46) per share for the quarter. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share. Leerink Partnrs also issued estimates for Solid Biosciences’ Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.50) EPS and Q4 2026 earnings at ($0.48) EPS.

Other research analysts have also recently issued reports about the stock. JMP Securities reissued a “market outperform” rating and set a $15.00 price objective on shares of Solid Biosciences in a research note on Friday, June 6th. JPMorgan Chase & Co. cut their price target on Solid Biosciences from $15.00 to $13.00 and set an “overweight” rating for the company in a report on Thursday. Cantor Fitzgerald set a $16.00 price target on Solid Biosciences and gave the stock an “overweight” rating in a report on Monday, July 21st. Piper Sandler decreased their price objective on Solid Biosciences from $20.00 to $17.00 and set an “overweight” rating on the stock in a research note on Friday, May 16th. Finally, Citigroup assumed coverage on Solid Biosciences in a research report on Thursday, June 26th. They set a “buy” rating and a $14.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Solid Biosciences has an average rating of “Buy” and an average price target of $15.00.

Solid Biosciences Trading Down 1.0%

Shares of SLDB opened at $6.11 on Friday. Solid Biosciences has a 12-month low of $2.41 and a 12-month high of $10.37. The stock has a market cap of $475.79 million, a P/E ratio of -2.18 and a beta of 2.44. The company has a 50-day moving average of $5.62 and a two-hundred day moving average of $4.44.

Solid Biosciences (NASDAQ:SLDB) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.09.

Institutional Trading of Solid Biosciences

Hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc increased its stake in shares of Solid Biosciences by 208.6% during the 2nd quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock valued at $29,000 after acquiring an additional 4,063 shares during the last quarter. Ameritas Investment Partners Inc. grew its holdings in Solid Biosciences by 205.5% in the second quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock valued at $33,000 after purchasing an additional 4,534 shares during the period. CWM LLC increased its position in Solid Biosciences by 15,188.5% during the first quarter. CWM LLC now owns 7,950 shares of the company’s stock worth $29,000 after purchasing an additional 7,898 shares during the last quarter. Corton Capital Inc. purchased a new position in Solid Biosciences during the fourth quarter worth approximately $41,000. Finally, Pallas Capital Advisors LLC acquired a new position in shares of Solid Biosciences in the 2nd quarter valued at $54,000. 81.46% of the stock is owned by institutional investors and hedge funds.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.